<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=580450&amp;fmt=gif">

the next-generation dried blood spot

It's time to stop using DBS cards. Here's why!

Die Alternative zu den DBS-Karten

Volumetric Absorptive Microsampling (VAMS™), the technology behind Mitra® devices, retains the benefits of DBS cards while solving for their limitations. 


Download these case studies from Exagen Diagnostics, GlaxoSmithKline, and others to see the following benefits vs DBS cards: 

  • Superior analytical performance  with better correlation to plasma

  • More simple, user-friendly dried blood collection approach

  • Compatibility with 96-well formats for fast sample extractions
  • Collect a homogeneous sample every time resulting in fewer rejects 


Mitra® microsampling combines the best of traditional wet sampling and dried blood spotting in a state-of-the-art collection device..

  • Collect a fixed volume (10, 20, or 30 μL) with < 4% RSD.
  • Reduce sample rejection rates with high quality blood samples.
  • Overcome the volumetric hematocrit (HCT) effect.
  • Simple, accurate self-collection with minimal training.
  • Easily inserted into common laboratory workflows

When Dried Blood Spot (DBS) cards debuted more than 50 years ago, they had significant advantages over traditional wet sampling, including simplicity, low cost, and ease of transportation.

But adoption has been hindered by regulatory concerns over the "Hematocrit (HCT) Effect," along with their automation limitations. In addition, incorrect spotting technique can lead to high sample rejection rates.

The FDA Class 1  Mitra® Microsampler is a novel specimen collection device that retains the advantages of Dried Blood Spot cards and solves for their limitations.